Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA3 | P07451 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA6 | P23280 | 2/20 | 0.40 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23928729 | 0.97 | — | — | |
| SCHEMBL5078489 | 0.82 | DNM1 (0.42) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL1530922 | 0.82 | DNM1 (0.42) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL28991670 | 0.79 | — | — | |
| SCHEMBL9750691 | 0.78 | — | — | |
| SCHEMBL2563068 | 0.78 | HTT (0.41) | CA12CA1CA2CA3CA4 | |
| SCHEMBL18704189 | 0.78 | HTT (0.41) | CA12CA1CA2CA3CA4 | |
| SCHEMBL2843073 | 0.78 | — | — | |
| SCHEMBL8935552 | 0.78 | HTT (0.41) | CA12CA1CA2CA3CA4 | |
| SCHEMBL17210714 | 0.78 | DNM1 (0.38) | DNM1CA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3231446-B1 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | PALOMO LTD (CY) | 2026-01-07 | — | — | EP | disclosed |
| EP-3350333-B2 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | MODERNATX INC (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250186624-A1 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | ARES CAPITAL CORPORATION, AS AGENT | 2025-06-12 | — | — | US | disclosed |
| US-12109274-B2 | Polynucleotides containing a stabilizing tail region | MODERNATX, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| EP-4159741-A1 | METHOD FOR PRODUCING A CHIMERIC POLYNUCLEOTIDE ENCODING A POLYPEPTIDE HAVING A TRIAZOLE-CONTAINING INTERNUCLEOTIDE LINKAGE | ModernaTX, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-4101930-A1 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | ModernaTX, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-3169693-B1 | CHIMERIC POLYNUCLEOTIDES | MODERNATX INC (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3350333-B1 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | MODERNATX INC (US) | 2021-10-27 | — | — | EP | disclosed |
| US-10407683-B2 | Circular polynucleotides | MODERNATX, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3169335-B1 | CIRCULAR POLYNUCLEOTIDES | MODERNA THERAPEUTICS INC (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20120115937-A1 | Ghrelin binding nucleic acids | NOXXON PHARMA AG (DE) | 2012-05-10 | — | — | US | disclosed |
| US-8101734-B2 | Ghrelin binding nucleic acids | NOXXON PHARMA AG (DE) | 2012-01-24 | — | — | US | disclosed |
| EP-1866412-A2 | GHRELIN BINDING NUCLEIC ACIDS | Noxxon Pharma AG (DE) | 2007-12-19 | — | — | EP | disclosed |
| EP-0878554-B1 | Detection of nucleic acids by fluorescence quenching | BECTON DICKINSON CO (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060258607-A1 | Ghrelin binding nucleic acids | NOXXON PHARMA AG (DE) | 2006-11-16 | — | — | US | disclosed |
| WO-2006108599-A2 | GHRELIN BINDING NUCLEIC ACIDS | NOXXON PHARMA AG (DE) | 2006-10-19 | — | — | WO | disclosed |
| US-6054279-A | Detection of nucleic acids by fluorescence quenching | BECTON DICKINSON AND COMPANY (US) | 2000-04-25 | — | — | US | disclosed |
| US-5919630-A | USING A OLIGONUCLEOTIDE DETECTOR | BECTON, DICKINSON AND COMPANY (US) | 1999-07-06 | — | — | US | disclosed |
| US-5846726-A | Detection of nucleic acids by fluorescence quenching | BECTON, DICKINSON AND COMPANY (US) | 1998-12-08 | — | — | US | disclosed |
| EP-0878554-A2 | Detection of nucleic acids by fluorescence quenching | Becton, Dickinson and Company (US) | 1998-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258607-A1 | Ghrelin binding nucleic acids | IGF2BP1, IGF2BP3, CRHBP | DNM1 1725/4885CA12 3400/4885CA1 3423/4885 |
| US-10407683-B2 | Circular polynucleotides | POLN, POLRMT, POLI | DNM1 1372/4885CA12 3226/4885CA1 4719/4885 |
| US-20120115937-A1 | Ghrelin binding nucleic acids | IGF2BP1, IGF2BP3, CRHBP | DNM1 1725/4885CA12 3400/4885CA1 3423/4885 |
| US-12109274-B2 | Polynucleotides containing a stabilizing tail region | POLR2E, POLN, PHAX | DNM1 1677/4885CA12 4728/4885CA1 4822/4885 |
| US-20250186624-A1 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | POLR2E, POLN, PHAX | DNM1 1677/4885CA12 4728/4885CA1 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.